Details for Patent: 10,695,339

Which drugs does patent 10,695,339 protect, and when does it expire?

Patent 10,695,339 protects COBENFY and is included in one NDA.

This patent has nineteen patent family members in nine countries.

Summary for Patent: 10,695,339

Title:	Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
Abstract:	The present disclosure provides a method of treating a central nervous system disorder in a patient in need thereof. The method comprises orally administering between 75 mg and 300 mg xanomeline salt and between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period, the central nervous system disorder being selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia, wherein use of the trospium chloride alleviates a side effect associated with use of the xanomeline salt.
Inventor(s):	Eric Elenko, Philip E. Murray, III, Andrew C. Miller
Assignee:	Puretech Health LLC , Puretech Management Inc
Application Number:	US16/444,206
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,695,339

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol-myers	COBENFY	trospium chloride; xanomeline tartrate	CAPSULE;ORAL	216158-001	Sep 26, 2024		RX	Yes	Yes						TREATMENT OF SCHIZOPHRENIA IN ADULTS
Bristol-myers	COBENFY	trospium chloride; xanomeline tartrate	CAPSULE;ORAL	216158-002	Sep 26, 2024		RX	Yes	No						TREATMENT OF SCHIZOPHRENIA IN ADULTS
Bristol-myers	COBENFY	trospium chloride; xanomeline tartrate	CAPSULE;ORAL	216158-003	Sep 26, 2024		RX	Yes	No						TREATMENT OF SCHIZOPHRENIA IN ADULTS

International Family Members for US Patent 10,695,339

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2804215
Denmark	3061821
European Patent Office	2456868
European Patent Office	3061821